# A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

> **NCT07356453** · PHASE1 · RECRUITING · sponsor: **FoRx Therapeutics AG** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** FORX-428

## Key facts

- **NCT ID:** NCT07356453
- **Lead sponsor:** FoRx Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2027-06
- **Final completion:** 2028-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07356453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07356453, "A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07356453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*